Clearside Biomedical Earnings Call Transcripts
Fiscal Year 2025
-
The session highlighted advances in suprachoroidal drug delivery, emphasizing the proprietary platform's growing acceptance and robust clinical data for CLS-AX in wet AMD. Flexible dosing, strong safety, and regulatory-aligned trial design position the product for phase III and commercialization, with funding discussions ongoing.
-
Leaders in suprachoroidal drug delivery are advancing a phase III-ready asset for wet AMD, aiming for 3–6 month dosing intervals and leveraging strong phase II data. Phase III trials will align with real-world practice, with over 50% of patients expected to reach six-month intervals.
-
The session highlighted advances in suprachoroidal drug delivery for retinal diseases, with a focus on the phase 3-ready CLS-AX for wet AMD and ongoing global partnerships. The company is optimizing trial design, expanding its pipeline, and actively seeking funding to support late-stage development.
-
The conference highlighted leadership in suprachoroidal drug delivery, with CLS-AX advancing to phase 3 for wet AMD after strong phase 2b results. Flexible dosing, safety, and strategic partnerships set the program apart, while pipeline expansion targets geographic atrophy with novel approaches.
Fiscal Year 2024
-
Positive phase II-B results for CLS-AX in wet AMD led to FDA alignment on pivotal phase III trials. Cash reserves fund operations into Q4 2025, with additional funding sought for phase III. Multiple global partnerships and regulatory milestones expand the suprachoroidal platform.
-
Phase II-B Odyssey trial in wet AMD showed strong efficacy and safe repeat dosing in a challenging patient group. Flexible dosing every three to six months and a superior safety profile via suprachoroidal delivery set the stage for a broad phase III in treatment-naive patients, with phase III launch expected in late 2025.
-
Positive phase 2b results for CLS-AX in wet AMD support phase 3 advancement, with strong safety, efficacy, and flexible dosing. Cash reserves of $23.6M fund operations into Q3 2025, and strategic partnerships and pipeline expansion continue to progress.
-
The ODYSSEY phase IIb trial in wet AMD met its primary endpoint, showing CLS-AX maintained stable vision and anatomical outcomes, with 67% of patients going six months without additional treatment and an 84% reduction in injection frequency. CLS-AX demonstrated a strong safety profile and is advancing to phase III studies with a flexible dosing regimen.
-
Suprachoroidal drug delivery is validated by FDA approval, real-world data, and strategic collaborations. The pipeline includes CLS-AX for wet AMD, with phase II-B data expected late Q3, and expansion plans into geographic atrophy. Suprachoroidal delivery offers safety, flexibility, and potential for longer dosing intervals, with strong IP protection and broad future applications.